Nathan Poterszman

Strasbourg, 67000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

[177Lu]Lu-PSMA extravasation: from quantitative imaging to clinical guidelines.

[177Lu]Lu-PSMA extravasation: from quantitative imaging to clinical guidelines.

Journal: Physics in medicine and biology

Published: January 15, 2026

Gravity versus pump-driven infusion in targeted radionuclide therapy: a model-based dosimetric evaluation of extravasation.

Gravity versus pump-driven infusion in targeted radionuclide therapy: a model-based dosimetric evaluation of extravasation.

Journal: EJNMMI physics

Published: September 11, 2025

Neuroendocrine peritoneal disease and [177Lu]DOTATATE peptide receptor radionuclide therapy: a therapeutic challenge with potential clinical complications.

Neuroendocrine peritoneal disease and [177Lu]DOTATATE peptide receptor radionuclide therapy: a therapeutic challenge with potential clinical complications.

Journal: European journal of nuclear medicine and molecular imaging

Published: February 03, 2025

Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [177Lu]Lu‑PSMA‑617 therapy in metastatic castration-resistant prostate cancer.

Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [177Lu]Lu‑PSMA‑617 therapy in metastatic castration-resistant prostate cancer.

Journal: Theranostics

Published: January 04, 2025

Organ-specific response to [177Lu]DOTATATE peptide receptor radionuclide therapy (PRRT) assessed by sequential [68Ga]DOTATOC PET/CT in patients with metastatic small intestine neuroendocrine tumors.

Organ-specific response to [177Lu]DOTATATE peptide receptor radionuclide therapy (PRRT) assessed by sequential [68Ga]DOTATOC PET/CT in patients with metastatic small intestine neuroendocrine tumors.

Journal: Endocrine

Published: November 02, 2024

A Hangover Under 177 Lu-PSMA-617 Therapy : A Red Flag for Brain 68 Ga-PSMA-11 PET/MRI?

A Hangover Under 177 Lu-PSMA-617 Therapy : A Red Flag for Brain 68 Ga-PSMA-11 PET/MRI?

Journal: Clinical nuclear medicine

Published: February 23, 2024

A bicentric retrospective study of the correlation of EAU BCR risk groups with 18F-PSMA-1007 PET/CT detection in prostate cancer biochemical recurrence.

A bicentric retrospective study of the correlation of EAU BCR risk groups with 18F-PSMA-1007 PET/CT detection in prostate cancer biochemical recurrence.

Journal: Scientific reports

Published: January 14, 2024

Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?

Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?

Journal: Frontiers in medicine

Published: October 12, 2023

Molecular imaging phenotyping of germline fumarate hydratase (FH) pathogenic variant-positive metastatic pheochromocytoma.

Molecular imaging phenotyping of germline fumarate hydratase (FH) pathogenic variant-positive metastatic pheochromocytoma.

Journal: European journal of nuclear medicine and molecular imaging

Published: April 09, 2023

Showing 1-9 of 9

Last Updated: 09/26/2026